Basel Pharmacoepidemiology Unit (BPU)

Research focus:

The research focus of the Basel Pharmacoepidemiology Unit (BPU) is pharmacoepidemiology and disease epidemiology. The main research tool is a large and well-validated database from the UK (CPRD), which encompasses over 10 million patient records. In addition, the BPU also has – under certain circumstances – access to claims data from a large health insurance in Switzerland. While in former years a clear focus was put on assessing adverse drug effects in the post-marketing phase IV, the BPU increasingly uses epidemiological methods to detect unexpected beneficial effects of drugs in large user groups, as well as to explore disease-disease associations, thereby covering a variety of medical topics (e.g. cardiovascular, CNS, ENT, ophthalmology, cancer and others).

Cooperation and networking:

The BPU is a research-oriented facility which collaborates with numerous pharmaceutical companies both in Switzerland and on an international level. The BPU closely collaborates with a group at Boston University and has, on a project basis, collaborations with research groups at the University of North Carolina and Regensburg. There is, also on a project basis, close research collaboration with various investigators from the Department of Medicine at the University of Basel.

Publications (full publication record: http://www.unispital-basel.ch/das-universitaetsspital/bereiche/medizinische-querschnittsfunktionen/kliniken-institute-abteilungen/spital-pharmazie/lehre-forschung/)

  • Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs and risk of Alzheimer’s disease: a population-based case-control study. Journal of the American Geriatric Society 2012;60:916-921
  • Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. American Journal of Gastroenterology 2012;107:620-626
  • Imfeld P, Bodmer M, Schuerch M, Jick SS, Meier CR. Seizures in patients with Alzheimer’s disease or vascular dementia: a population-based nested case-control analysis. Epilepsia 2013;54:700-707
  • Imfeld P, Pernus YB, Jick SS, Meier CR. Epidemiology, co-morbidities, and medication use of patients with Alzheimer’s disease or vascular dementia in the UK. Journal of Alzheimers Disease 2013;35:565-573
  • Imfeld P, Bodmer M, Schuerch M, Jick SS, Meier CR. Risk of incident stroke in patients with Alzheimer disease or vascular dementia. Neurology 2013;81:910-919
  • Hong J. Meier CR, Sandler RS, Jick SS, Stürmer T. Risk of colorectal cancer after initiation of orlistat: a matched cohort study. British Medical Journal (BMJ) 2013;347:f5039
  • Spoendlin J, Voegel JJ, Jick SS, Meier CR. Spironolactone may reduce the risk of incident rosacea. Journal of Investigative Dermatology 2013;133:2480-2483
  • Bruderer S, Jick SS, Bodmer M. Meier CR. Use of diuretics and risk of incident gout: Population-based case-control study. Arthritis & Rheumatism 2013 Oct 21. Doi 10.1002/art.38203
  • Becker C, Jick SS, Meier CR, Bodmer M. Metformin and the risk of endometrial cancer: a case-control analysis. Gynecologic Oncology 2013;129:565-569
  • Spoendlin J, Voegel JJ, Jick SS, Meier CR. Spironolactone may reduce the risk of incident rosacea. Journal of Investigative Dermatology 2013;133:2480-2483
  • Spoendlin J, Voegel JJ, Jick SS, Meier CR. Migraine, triptans, and the risk of developing rosacea – a population-based study within the United Kingdom. Journal of the American Academy of Dermatology 2013;69:399-406
  • Becker C, Jick SS, Meier CR, Bodmer M. Metformin and the risk of head and neck cancer: a case-control analysis. Diabetes, Obesity and Metabolism 2014;16:1148-1154
  • Layton JB, Meier CR, Sharpless J, Stürmer T, Jick SS, Brookhart MA. Comparative safety of testosterone dosage forms. JAMA Internal Medicine 2015; in press
  • Imfeld P, Bodmer M. Jick SS, Meier CR. Benzodiazepine use and risk of developng Alzheimer’s disease or vascular dementia: a case-control analysis. Drug Safety 2015;38:909-919